Claims for Patent: 10,172,890

Summary for Patent: 10,172,890

Title:	Topical skin care compositions and methods
Abstract:	Topical compositions containing lysate of human parthenogenetic stem cells (hpSCs), preferably within a liposomal dispersion, that reduce the visible signs of skin aging and/or cellulite.
Inventor(s):	Semechkin; Andrey (Rancho Santa Fe, CA), Turovets; Nikolay A. (Carlsbad, CA), Agapova; Larisa S. (Moscow, RU), Kern; Russell A. (Rancho Santa Fe, CA), Janus; Jeffrey D. (San Diego, CA)
Assignee:
Application Number:	13/196,824
Patent Claims:	1. A method for improving one or more signs of skin aging by (i) reducing the depth or number of facial fine lines and wrinkles or (ii) increasing skin elasticity or firmness or (iii) improving skin hydration comprising the step of applying to the skin a topical composition comprising a lysate of human parthenogenetic stem cells, wherein lysate of human parthenogenetic stem cells (hpSCs) is produced by a process comprising the steps of (a) passaging and then incubating hpSCs from blastocyst inner cell mass in cell culture medium, (b) separating the hpSCs from the cell culture medium and washing the hpSCs with calcium- and magnesium-free phosphate based saline (c) treating the hpSCs with collagenase type IV, (d) separating the collagenase from hpSCs, (e) washing the hpSCs with calcium- and magnesium-free phosphate based saline and (f) harvesting and lysing the hpSCs. 2. The method of claim 1 wherein the topical composition further comprises at least one antioxidant. 3. The method of claim 2 wherein the at least one antioxidant is selected from the group consisting of Coenzyme Q10 and its analogs, ascorbic acid and its salts, ascorbyl esters of fatty acids, tocopherol and its esters, butylated hydroxybenzoic acids and their salts, and retinoids. 4. The method of claim 1 wherein the lysate of human parthenogenetic stem cells is present in the topical composition within a liposomal dispersion. 5. The method of claim 4 wherein the lysate of human parthenogenetic stem cells is present within a liposomal dispersion at a concentration of from 1.times.10.sup.3 to 1.times.10.sup.9 human parthenogenetic stem cells per one gram of liposomal dispersion. 6. The method of claim 5 wherein the liposomal dispersion further comprises at least one lipid-protective agent. 7. The method of claim 6 wherein the lipid-protective agent is a fat-soluble antioxidant selected from the group consisting of tocopheryl acetate, retinyl palmitate, butylated hydroxytoluene, butylated hydroxyanisole, ascorbyl palmitate and mixtures thereof. 8. The method of claim 7 wherein the topical composition further comprises one or more of a second antioxidant, a vitamin or vitamin derivative, or a short-chain, elastin/collagen stimulating peptide. 9. The method of claim 1 or 4 wherein the human parthenogenetic stem cells are cultured in feeder-free medium. 10. The method of claim 8 wherein the human parthenogenetic stem cells are harvested and lysed without the use of proteinase inhibitors. 11. The method of claim 1 or 4 wherein the topical composition further comprises Coenzyme Q10 and vitamin E or a derivative thereof. 12. The method of claim 4 wherein the liposomal dispersion containing the lysate of human parthenogenetic stem cells is present in the topical composition at 1% to 20% by weight of the composition. 13. The method of claim 12 wherein the topical composition further comprises a B vitamin complex. 14. The method of claim 13 wherein the topical composition comprises (a) 1% to 20% by weight of a liposomal dispersion containing the lysate of human parthenogenetic stem cells (b) Coenzyme Q10 and vitamin E or a derivative thereof (c) a vitamin B complex; (d) vitamin P. 15. The method of claim 14 wherein the topical composition further comprises one or more of a retinoid, a natural moisturizing factor, a dermal lipomimetic or a sunscreen. 16. A method of reducing the appearance of cellulite by applying to the skin of a postpubertal woman exhibiting "orange peel" texture, dimpling or stretch marks a topical composition comprising a lysate of human parthenogenetic stem cells wherein lysate of human parthenogenetic stem cells (hpSCs) is produced by a process comprising the steps of (a) passaging and then incubating hpSCs from blastocyst inner cell mass in cell culture medium, (b) separating the hpSCs from the cell culture medium and washing the hpSCs with calcium- and magnesium-free phosphate based saline (c) treating the hpSCs with collagenase type IV, (d) separating the collagenase from hpSCs, (e) washing the hpSCs with calcium- and magnesium-free phosphate based saline and (f) harvesting and lysing the hpSCs the topical composition further comprises at least one of an anti-oxidant, an anti-edema ingredient, an anti-inflammatory, an ingredient that stimulates lipolysis, an ingredient that improves/increases microvascular perfusion, an ingredient that promotes production of collagen or elastins. 17. The method of claim 16 wherein the lysate of human parthenogenetic stem cells is present in the topical composition within a liposomal dispersion. 18. The method of claim 17 wherein the topical composition further comprises Coenzyme Q10 and vitamin E or a derivative thereof.

Details for Patent 10,172,890

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2030-08-03